| Literature DB >> 26101577 |
Alessandra Tolomelli1, Monica Baiula2, Angelo Viola1, Lucia Ferrazzano1, Luca Gentilucci1, Samantha Deianira Dattoli2, Santi Spampinato2, Eusebio Juaristi3, Margarita Escudero3.
Abstract
A novel class of dehydro-β-proline-containing peptidomimetics, designed to be effective as α4β1 integrin ligands, has been developed on the basis of the fundamental requirements for the interactions of these transmembrane receptors with bioactive ligands. Dehydro-β-proline ring has been synthesized through an original pathway, involving ring closing metathesis of a diallylamino derivative. The synthesized products showed to be effective and selective as α4β1 integrin antagonists and displayed IC50 values in the nanomolar range in cell adhesion inhibition assays and in VCAM-1-induced phosphorylation of extracellular-signal-regulated kinases. Significant activity was observed also toward the homologous integrin α4β7, while they did not display any activity toward selected members of β1, β2, and β3 families. A strong dependence on the stereochemistry of the heterocyclic central core could be observed. The great importance of α4β1 integrin in chronic inflammatory and autoimmune diseases suggests a possible exploitation of these ligands as lead compounds for therapeutic tools development.Entities:
Keywords: Small-molecule inhibitors; enantiomers; inflammation; integrin ligands; peptidomimetics
Year: 2015 PMID: 26101577 PMCID: PMC4468404 DOI: 10.1021/acsmedchemlett.5b00125
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345